Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHA is an abbreviation that refers to two distinct compounds in the provided context: Docosahexaenoic acid and Dihydroartemisinin. Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid vital for neurological growth and cognitive function. It acts as a precursor to specialized pro-resolving mediators like Maresin1, modulates microglial autophagy, and influences lipid metabolism. Dihydroartemisinin (DHA) is a derivative of artemisinin, known for its antimalarial and anticancer activities. It exerts its effects by inducing ferroptosis, modulating immune cell activity (Tfh, B, and Treg cells), and targeting various proteins involved in cancer progression such as AR, CASP3, CDK1, CDK4, PTK2, and MMP9.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DHA.